ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pathology Bone Joint"

  • Abstract Number: 0852 • ACR Convergence 2024

    3-dimensional Shape Changes of the Knee over 4 Years Are Linear and Progressive but Much More Rapid in Osteoarthritic Joints: Data from the Osteoarthritis Initiative

    Alan Brett1, Philip G Conaghan2 and Michael Bowes3, 1Imorphics, Austin, TX, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Imorphics, Manchester, United Kingdom

    Background/Purpose: The specific bony changes of osteophyte growth and “bone attrition” (broadening and flattening of the femoral condyles) associated with OA have been recognized in…
  • Abstract Number: 0418 • ACR Convergence 2023

    Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis

    Edoardo Spolaore1, Edward DiCarlo2, Daniel Ramirez2, Melanie Smith2, Amit Lakhanpal2, Bella Mehta3, Laura Donlin2, Susan Goodman2 and Dana Orange4, 1HSS, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…
  • Abstract Number: 0503 • ACR Convergence 2023

    Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging

    Siba Raychaudhuri1, Yasser Abdelhafez2, Dario Mazza2, Smriti K Raychaudhuri3 and Abhijit Chaudhari4, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2University of California Davis, Sacramento, CA, 3VA Sacramento Medical Center, Mather, CA, 4UC Davis School of Medicine, Sacramento, CA

    Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
  • Abstract Number: 0862 • ACR Convergence 2023

    Role of CRTAC1 as a Biomarker of Osteoarthritis

    Aneta Pekacova1, Jiri Baloun2, Adela Navratilova3, Lucia Ondrejcakova4, Jana Zborovjanova4, Petr Fulin5, Rastislav Ballay6, Michal Tomcik7 and Ladislav Senolt8, 1First faculty of medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5First Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic, 6First Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 7Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 8Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic

    Background/Purpose: Cartilage acidic protein-1 (CRTAC1) has been recently considered a promising biomarker of osteoarthritis (OA) progression (1,2). The aim of this study is to compare…
  • Abstract Number: 1630 • ACR Convergence 2023

    Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis

    Diyu Fisher1, Dana Orange2, Melanie Smith3, Bella Mehta4, Edoardo Spolaore5, Edward DiCarlo3, Dongmei Sun3, Laura Donlin3 and Susan Goodman3, 1Stony Brook Medicine, Port Jefferson Station, NY, 2The Rockefeller University, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 5HSS, New York, NY

    Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…
  • Abstract Number: 1919 • ACR Convergence 2023

    Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series

    Yasmine Elfarra1, Edward DiCarlo2, Jonathan Vigdorchik2, Carlos Aude3, Nilasha Ghosh3, Anne Bass3 and Karmela Kim Chan2, 1Weill Cornell, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of cancer treatment dramatically, but because of their mechanism of action they are also known to…
  • Abstract Number: 2066 • ACR Convergence 2023

    Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy

    Diane Horowitz1, Darren Tabechian2, Ami Ben-Artzi3, Karina Torralba4 and Arthur Mandelin5, 1Northwell Health, Great Neck, NY, 2University of Rochester Medical Center, Rochester, NY, 3Ami Ben Artzi, MD, San Diego, CA, 4Loma Linda University, Loma Linda, CA, 5Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Ultrasound guided synovial biopsy (UGSB) is a minimally invasive, safe and effective tool to obtain synovium for clinical and research purposes. Described in Europe…
  • Abstract Number: 0726 • ACR Convergence 2021

    Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm

    Robert Fountaine1, Robert Dworkin2, Anne Hickman1, Glenn Pixton3, Ed Whalen4, Christine West1 and Kenneth Verburg1, 1Pfizer Inc., Groton, CT, 2University of Rochester, Rochester, NY, 3Pfizer Inc., Morrisville, NC, 4Pfizer Inc., New York, NY

    Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
  • Abstract Number: 1890 • ACR Convergence 2021

    Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis

    Hannah Nelson1, Ellen Gravallese2, Julia Charles1 and Christian Jacome-Galarza1, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…
  • Abstract Number: 1897 • ACR Convergence 2021

    A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout

    Nicola Dalbeth1, Anthony Doyle1, Karen Billington1, Gregory Gamble1, Paul Tan1, Kieran Latto1, Trish Parshu Ram1, Ravi Narang1, Rachel Murdoch1, David Bursill1, Borislav Mihov1, Lisa Stamp2 and Anne Horne1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
  • Abstract Number: 0085 • ACR Convergence 2020

    Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition

    Fadi Charouf1, Netanel Karbian1, Itamar Altman1, Yakov Fellig1 and Dror Mevorach1, 1Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
  • Abstract Number: 0793 • ACR Convergence 2020

    Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome

    Benjamin Van Espen1, Andrew Wilson1, Gregory Seumois2, Narayanan Perumal3, Robert Benschop4, Gary Firestein5, Nunzio Bottini5 and Stephanie Stanford1, 1University of California, San Diego, La Jolla, 2La Jolla Institute for Immunology, La Jolla, 3Eli Lilly, Indianapolis, 4Eli Lilly and Company, Indianapolis, IN, 5University of California, San Diego, La Jolla, CA

    Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…
  • Abstract Number: 0796 • ACR Convergence 2020

    Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables

    Hayley Carr1, Ilfita Sahbudin1, Mark Maybury1, Bernard Dyke2, Jason Turner3, Nicola Gullick4, Karim Raza5, Dagmar Scheel-Toellner1 and Andrew Filer1, 1Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 2Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, 3Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, 4University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom

    Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
  • Abstract Number: 0875 • ACR Convergence 2020

    Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study

    Iain McInnes1, Hector Chinoy2, Darren Asquith3, Abigail White3 and Corine Gaillez4, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2The University of Manchester, Manchester, United Kingdom, 3Novartis Pharmaceuticals UK Ltd., London, United Kingdom, 4Novartis Pharma AG, Basel, Switzerland

    Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
  • Abstract Number: 1854 • ACR Convergence 2020

    NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis

    Siba Raychaudhuri1 and Smriti Raychaudhuri2, 1UC Davis, School of Medicine, Davis, CA, 2VA Sacramento Medical Center, Davis, CA

    Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology